These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34037253)

  • 1. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.
    Barbé J; Poreaux C; Remen T; Schoeffler A; Cloché V; Schmutz JL; Escobar G; Busztejn AC
    Int J Dermatol; 2021 Dec; 60(12):1520-1528. PubMed ID: 34037253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case-Control Study.
    Marolo P; Ribero S; Caselgrandi P; Ghilardi A; de Sanctis U; Parisi G; Fallico M; Borrelli E; Ortoncelli M; Gelato F; Mastorino L; Tibaldi T; Roccuzzo G; Quaglino P; Reibaldi M
    Cornea; 2024 Feb; 43(2):221-227. PubMed ID: 37404010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
    Napolitano M; Di Guida A; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.
    Popiela MZ; Barbara R; Turnbull AMJ; Corden E; Martinez-Falero BS; O'Driscoll D; Ardern-Jones MR; Hossain PN
    Eye (Lond); 2021 Dec; 35(12):3277-3284. PubMed ID: 33504973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
    Achten R; Thijs J; van der Wal M; van Luijk C; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Allergy; 2023 Aug; 78(8):2266-2276. PubMed ID: 36934403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dupilumab-related blepharoconjunctivitis: Recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: Which management approach?].
    Doan S; Arnould L; Febvay C; Fournié P; Gueudry J; Labalette P; Ouilhon C; Tran TH; Vabres B; Barbarot S; Bouaziz JD; Du-Thanh A; Jachiet M; Seneschal J; Soria A; Staumont-Sallé D; Baudouin C; Mortemousque B
    J Fr Ophtalmol; 2022 Mar; 45(3):277-287. PubMed ID: 35078645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
    Ferrucci S; Angileri L; Tavecchio S; Fumagalli S; Iurlo A; Cattaneo D; Marzano AV; Maronese CA
    J Dermatolog Treat; 2022 Aug; 33(5):2587-2592. PubMed ID: 35261333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
    Achten RE; Van Luijk C; Van der Rijst L; Bakker D; Spekhorst L; Zuithoff N; Schuttelaar M; Romeijn G; Voorberg A; Kamsteeg M; Haeck I; De Graaf M; Thijs J; De Boer J; De Bruin-Weller M
    Acta Derm Venereol; 2022 Mar; 102():adv00666. PubMed ID: 35098318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis.
    Felfeli T; Georgakopoulos JR; Jo CE; Mimouni M; Piguet V; Drucker AM; Yeung J; Chan CC
    Cornea; 2022 Oct; 41(10):1242-1247. PubMed ID: 34843182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration.
    Wang Y; Jorizzo JL
    J Am Acad Dermatol; 2021 Apr; 84(4):1010-1014. PubMed ID: 33725800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy.
    Achten R; Thijs J; van der Wal M; van Luijk C; Bakker D; Knol E; van Luin M; El Amrani M; Delemarre E; Elfiky AMI; de Boer J; van Wijk F; de Graaf M; de Bruin-Weller M
    Clin Exp Allergy; 2024 Apr; 54(4):241-252. PubMed ID: 38332535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.